Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the effectiveness of (a) clinical trials and (b) other treatment options for glioblastoma.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidelines for the National Health Service on best practice based on an assessment of clinical and cost effectiveness. NICE keeps its guidelines under review and uses the best available evidence to develop its recommendations. Its surveillance programme proactively explores whether there is any new evidence to contradict, reinforce or clarify its guideline recommendations.

NICE’s guideline on brain tumours and brain metastases in people aged 16 years old or over was most recently updated in 2021 and makes recommendations on the management of grade IV gliomas. The NHS is expected to take NICE guidelines fully into account in ensuring that services meet the needs of their local populations.

In May 2018, the Government announced £40 million for brain tumour research as part of the Tessa Jowell Brain Cancer Mission, through the National Institute for Health and Care Research. This includes funding for glioblastoma research.